Plexision Aims to Deliver Single-Day Results for Organ Transplant Rejection Testing With Antigen Dx

31, Oct 2022


Plexision Aims to Deliver Single-Day Results for Organ Transplant Rejection Testing With Antigen Dx

News osutra_adm1n

NEW YORK— Diagnostics startup Plexision aims to cut down delays in testing for organ transplant rejection with an antigen-based blood test for early signs a patient's immune system is attacking the donated tissue.

https://www.360dx.com/point-care-testing/plexision-aims-deliver-single-day-resu…

Categories

Recent Posts

  • …
  • …
  • …

logo

Developing cellular biomarkers for personalized diagnosis and drug development in infectious diseases, solid organ transplantation, as well as immunological disorders.

CONTACT US

  • Contact us
    4424 Penn Ave., #202,
    Pittsburgh, PA 15224 USA
  • Mail Us
    info@plexision.com
  • Phone
    +1 (855) 753-9474
© Copyright Plexision 2020. All Rights Reserved.

About

Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to

  • - Assess disease risk for several immunological disorders.
  • - Predict the success of a drug for a specific patient.
  • - Develop dosing recommendations for new immunological drugs.

Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.

Contact